van Houte Hans 4

What Happened

• Hans van Houte, CFO of Nurix Therapeutics (NRIX), had RSUs convert to common shares on 2026-04-30 (three separate partial vesting events totaling 8,608 shares at $0 cost) and sold 2,388 shares in an open-market sell-to-cover transaction for proceeds of $39,749 (weighted average price $16.65).
• The conversion entries are reported as derivative exercises (transaction code M) because each RSU converts into one share on vesting; the sale was routine tax-withholding (not a discretionary market sale).

Key Details

• Transaction date: 2026-04-30.
• Conversion (exercise) of RSUs: 2,000 + 3,750 + 2,858 = 8,608 shares acquired at $0.00 (code M).
• Open-market sale: 2,388 shares sold at a weighted average price of $16.65 for total proceeds of $39,749. Reported sale price range: $16.51–$16.78 (footnote F2).
• Footnotes: F1 states the sale was a mandatory "sell-to-cover" to satisfy tax withholding on RSU vesting (not a discretionary trade). F3–F7 describe that each RSU equals one share and list vesting schedules (1/12 quarterly over three years for the awards).
• Shares owned after the transactions are not specified in the provided filing.
• No late filing flag is indicated in the summary information.

Context

• This is a typical cashless/sell-to-cover event following RSU vesting: RSUs converted to shares (exercise/conversion) and a portion sold immediately to pay required taxes. Such transactions are routine and do not necessarily indicate a change in insider sentiment.